These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 22434314)

  • 1. Management of hepatocellular carcinoma: beyond sorafenib.
    Chan SL; Mok T; Ma BB
    Curr Oncol Rep; 2012 Jun; 14(3):257-66. PubMed ID: 22434314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib: where do we go from here?
    Siegel AB; Olsen SK; Magun A; Brown RS
    Hepatology; 2010 Jul; 52(1):360-9. PubMed ID: 20578152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
    Huynh H; Choo SP; Toh HC; Tai WM; Chung AY; Chow PK; Ong R; Soo KC
    Curr Cancer Drug Targets; 2011 Oct; 11(8):944-53. PubMed ID: 21834756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib for liver cancer: the horizon broadens.
    Johnson P; Billingham L
    Lancet Oncol; 2009 Jan; 10(1):4-5. PubMed ID: 19111238
    [No Abstract]   [Full Text] [Related]  

  • 5. Evolution of systemic therapy of advanced hepatocellular carcinoma.
    Yau T; Chan P; Epstein R; Poon RT
    World J Gastroenterol; 2008 Nov; 14(42):6437-41. PubMed ID: 19030192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
    Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P
    BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib in hepatocellular carcinoma.
    Josephs DH; Ross PJ
    Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Targeted therapies in hepatocellular carcinoma].
    Bouattour M; Marijon H; Dreyer C; Faivre S; Raymond E
    Presse Med; 2010; 39(7-8):753-64. PubMed ID: 20378303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted agents and systemic therapy in hepatocellular carcinoma.
    Ang C; O'Reilly EM; Abou-Alfa GK
    Recent Results Cancer Res; 2013; 190():225-46. PubMed ID: 22941024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.
    Ranieri G; Gadaleta-Caldarola G; Goffredo V; Patruno R; Mangia A; Rizzo A; Sciorsci RL; Gadaleta CD
    Curr Med Chem; 2012; 19(7):938-44. PubMed ID: 22214462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib.
    Wich C; Agaimy A; Strobel D; Wissniowski TT; Hartmann A; Ocker M
    World J Gastroenterol; 2010 Jul; 16(28):3592-6. PubMed ID: 20653070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hepatocellular carcinoma].
    Yamashita T; Arai K; Kaneko S
    Nihon Rinsho; 2010 Oct; 68(10):1861-5. PubMed ID: 20954330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma.
    Huynh H; Ong RW; Li PY; Lee SS; Yang S; Chong LW; Luu DA; Jong CT; Lam IW
    Anticancer Agents Med Chem; 2011 Jul; 11(6):560-75. PubMed ID: 21554207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hepatocellular carcinoma - long-term treatable disease].
    Fínek J
    Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B; Di Maio M
    J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Yau T; Pang R; Chan P; Poon RT
    Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study.
    Zhao JD; Liu J; Ren ZG; Gu K; Zhou ZH; Li WT; Chen Z; Xu ZY; Liu LM; Jiang GL
    Radiat Oncol; 2010 Feb; 5():12. PubMed ID: 20149262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
    Burak KW
    Oncology (Williston Park); 2011 Mar; 25(3):296, 298, 300. PubMed ID: 21548474
    [No Abstract]   [Full Text] [Related]  

  • 19. Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system.
    Kudo M; Tateishi R; Yamashita T; Ikeda M; Furuse J; Ikeda K; Kokudo N; Izumi N; Matsui O
    Clin Drug Investig; 2012 Aug; 32 Suppl 2():37-51. PubMed ID: 22873626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular targeted therapies in hepatocellular carcinoma.
    Llovet JM; Bruix J
    Hepatology; 2008 Oct; 48(4):1312-27. PubMed ID: 18821591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.